Table 1 Participant characteristics
Younger adults | Older adults (all) | Older adults (Fc-functionality subgroup) | |
|---|---|---|---|
Size, n | 64 | 50 | 38 |
Age in years, median (range, SD) | 33 (18–47, 7.0) | 70 (65–83, 3.8) | 69 (65–77, 3.3) |
Female sex, n (%) | 42 (66) | 23 (46) | 18 (47) |
Confirmed SARS-CoV-2 infection | |||
After second dose, before post-third sample, n (%) | 4 (6.3) | 2 (4.2) | 1 (2.8) |
After second dose, before post-fifth sample, n (%) | NA | 20 (41) | 13 (35) |
Vaccine typea | |||
First dose Pfizer-BioNTech, n (%) | 64 (100) | 50 (100) | 38 (100) |
Second dose Pfizer-BioNTech, n (%) | 64 (100) | 50 (100) | 38 (100) |
Third dose Moderna, n (%) | 1 (1.6) | 46 (92) | 35 (92) |
Third dose Pfizer-BioNTech, n (%) | 63 (98) | 4 (8)b | 3 (8) |
Fourth dose Moderna, n (%) | NA | 35 (70) | 26 (68) |
Fourth dose Pfizer-BioNTech, n (%) | NA | 15 (30) | 12 (32) |
Fifth dose Moderna (bivalent), n (%) | NA | 48 (98)c | 36 (97)c |
Fifth dose Pfizer-BioNTech (bivalent), n (%) | NA | 1 (2)c | 1 (3)c |
Vaccination interval in days | |||
First to second dose, median (range, SD) | 35 (32–39, 1.0) | 35 (31–36, 0.7) | 35 (35–36, 0.3) |
Second to third dose, median (range, SD) | 162 (140–310, 21) | 208 (160–295, 21) | 208 (160–295, 21) |
Third to fourth dose, median (range, SD) | NA | 103 (90–204, 36) | 105 (90–204, 38) |
Fourth to fifth dose, median (range, SD) | NA | 182 (102–221, 37)c | 182 (105–221, 38)c |
Sampling interval in days | |||
Post-second dose, median (range, SD) | 30 (28–44, 2.5) | 32 (28–40, 3.1) | 32 (28–40, 3.2) |
Post-second dose FU, median (range, SD) | 164 (141–310, 21) | 200 (169–289, 20) | 197 (169–289, 21) |
Post-third dose, median (range, SD) | 31 (25–39, 2.7) | 30 (23–46, 4.8) | 30 (23–46, 4.9) |
Post-fourth dose FU, median (range, SD) | NA | 166 (75–216, 34) | 166 (75–216, 35) |
Post-fifth dose, median (range, SD) | NA | 30 (23–42, 4.8)c | 30 (23–42, 4.9)c |